BOPI 01 BR/2024 REPERTOIRE NUMERIQUE 17 Embassy, Entrance-St. John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) A plant (1) for storing energy comprises a casing (5) for the storage of a working fluid other than atmospheric air, in gaseous phase and in equilibrium of pressure with the atmosphere; a tank (9) for the storage of said working fluid in liquid or supercritical phase with a temperature close to the critical temperature; wherein said critical temperature is close to the ambient temperature. The plant (1) is configured to perform a closed cyclic thermodynamic transformation (CTT), first in one direction in a charge configuration and then in an opposite direction in a discharge configuration, between said casing (5) and said tank (9); wherein in the charge configuration the plant (1) stores heat and pressure and in the discharge configuration the plant generates energy. The plant (1) is also configured to define a closed circuit and to perform a closed thermodynamic cycle (TC) in the closed circuit with at least a part of the working fluid, optionally while the plant (1) is in the charge configuration or in the discharge configuration. ________________________________________ (11) 21340 Consulter le mémoire (51) A61K 31/4402 (2018.01); A61K 31/4415 (2018.01); A61K 9/48 (2018.01) ; A61K 9/50 (2018.01) (21) 1202200381 - PCT/EP2021/057555 (22) 24/03/2021 (30) EP n° 20382227.5 du 25/03/2020 (54) A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation. (72) SAURA I VALLS, Marc (ES); NEBOT TROYANO, Joaquin (ES); ROCA I JUANES, Ramon M. (ES); COLOMBO, Giuseppe (IT) et MALDONADO VILLEGAS, Adrià (ES) (73) ITALFARMACO S.P.A., Viale Fulvio Testi, 330, I-20126 MILANO (MI) (IT) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS SARL, The House of Gideon, Golf/Bastos Quarter, Opposite The American Embassy, Entrance-St. John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) The present invention relates to modified release multiple unit oral dosage form comprising: a first plurality of modified release pellets of doxylamine comprising: a pharmaceutically acceptable inert nucleus; an inner active coating layer comprising a doxylamine; optionally an intermediate enteric release coating layer; and an external modified release coating layer; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable salt thereof comprising: a pharmaceutically acceptable inert nucleus; an inner active coating layer comprising pyridoxine or a pharmaceutically acceptable salt thereof; and an external modified release coating layer; wherein the particle size of the pharmaceutically acceptable inert nucleus of the first and the second plurality of pellets is such that at least 90% of the inert nucleus have a particle size from 300 µm to 1700 µm and a particle size variability of not more than200 µm measured by analytical sieving. It also relates to a process for its preparation and its use in therapy.
RkJQdWJsaXNoZXIy MTM1NDc3MA==